Richard Stephen 4

What Happened

• Richard Stephen, a director of Anika Therapeutics, was granted 10,402 restricted stock units (RSUs) on June 18, 2026. The grant reported an acquisition price of $0.00 (total $0 reported), because these are compensation RSUs rather than an open‑market purchase.

Key Details

• Transaction date: 2026-06-18; reported filing date (Form 4): 2026-06-23.
• Award: 10,402 RSUs @ $0.00 per unit (reported acquisition value $0).
• Vesting: RSUs vest in full on the earlier of the Company’s 2027 annual meeting or June 18, 2027 (per filing footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Form 4 was filed 6/23/2026 — appears to be filed after the 2-business‑day deadline (late filing).

Context

• RSUs are a contingent right to receive one share each upon vesting; they are compensation, not an immediate cash purchase or sale. Such awards are routine director compensation and do not by themselves indicate buying or selling sentiment. Upon vesting the RSUs typically convert to shares and may be subject to tax withholding or other settlement terms.